|
1
|
Pashos CL, Botteman MF, Laskin BL and
Redaelli A: Bladder cancer: Epidemiology, diagnosis, and
management. Cancer Pract. 10:311–322. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gwangwa MV, Joubert AM and Visagie MH:
Crosstalk between the Warburg effect, redox regulation and
autophagy induction in tumourigenesis. Cell Mol Biol Lett.
23:202018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cantor JR and Sabatini DM: Cancer cell
metabolism: One hallmark, many faces. Cancer Discov. 2:881–898.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Henry J, Guillotte A, Luberto C and Del
Poeta M: Characterization of inositol
phospho-sphingolipid-phospholipase C 1 (Isc1) in Cryptococcus
neoformans reveals unique biochemical features. FEBS Lett.
585:635–640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng H, Luo C, Wu X, Zhang Y, He Y, Wu Q,
Xia Y and Zhang J: shRNA targeting PLCε inhibits bladder cancer
cell growth in vitro and in vivo. Urology. 78:474 e477–e411. 2011.
View Article : Google Scholar
|
|
10
|
Jiang T, Liu T, Li L, Yang Z, Bai Y, Liu D
and Kong C: Knockout of phospholipase Cε attenuates
N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder
tumorigenesis. Mol Med Rep. 13:2039–2045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang X, Ou L, Tang M, Wang Y, Wang X, Chen
E, Diao J, Wu X and Luo X: Knockdown of PLCε inhibits inflammatory
cytokine release via STAT3 phosphorylation in human bladder cancer
cells. Tumour Biol. 36:9723–9732. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grivennikov SI and Karin M: Dangerous
liaisons: STAT3 and NF-kappaB collaboration and crosstalk in
cancer. Cytokine Growth Factor Rev. 21:11–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ihle JN: STATs: Signal transducers and
activators of transcription. Cell. 84:331–334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li M, Jin R, Wang W, Zhang T, Sang J, Li
N, Han Q, Zhao W, Li C and Liu Z: STAT3 regulates glycolysis via
targeting hexokinase 2 in hepatocellular carcinoma cells.
Oncotarget. 8:24777–24784. 2017.PubMed/NCBI
|
|
16
|
Le A, Cooper CR, Gouw AM, Dinavahi R,
Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang
CV: Inhibition of lactate dehydrogenase A induces oxidative stress
and inhibits tumor progression. Proc Natl Acad Sci USA.
107:2037–2042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Augoff K, Hryniewicz-Jankowska A and
Tabola R: Lactate dehydrogenase 5: An old friend and a new hope in
the war on cancer. Cancer Lett. 358:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Magers MJ, Lopez-Beltran A, Montironi R,
Williamson SR, Kaimakliotis HZ and Cheng L: Staging of bladder
cancer. Histopathology. 74:112–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wake MS and Watson CJ: STAT3 the
oncogene-still eluding therapy? FEBS J. 282:2600–2611. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kelley GG, Reks SE, Ondrako JM and Smrcka
AV: Phospholipase C(epsilon): A novel Ras effector. EMBO J.
20:743–754. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hicks SN, Jezyk MR, Gershburg S, Seifert
JP, Harden TK and Sondek J: General and versatile autoinhibition of
PLC isozymes. Mol Cell. 31:383–394. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wing MR, Snyder JT, Sondek J and Harden
TK: Direct activation of phospholipase C-epsilon by Rho. J Biol
Chem. 278:41253–41258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cullen PJ: Ras effectors: Buying shares in
Ras plc. Curr Biol. 11:R342–R344. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abnet CC, Freedman ND, Hu N, Wang Z, Yu K,
Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, et al: A shared
susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma
and esophageal squamous cell carcinoma. Nat Genet. 42:764–767.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smrcka AV, Brown JH and Holz GG: Role of
phospholipase Cε in physiological phosphoinositide signaling
networks. Cell Signal. 24:1333–1343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ou L, Guo Y, Luo C, Wu X, Zhao Y and Cai
X: RNA interference suppressing PLCE1 gene expression decreases
invasive power of human bladder cancer T24 cell line. Cancer Genet
Cytogenet. 200:110–119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ling Y, Chunli L, Xiaohou W and Qiaoling
Z: Involvement of the PLCε/PKCα pathway in human BIU-87 bladder
cancer cell proliferation. Cell Biol Int. 35:1031–1036. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liberti MV and Locasale JW: The Warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ristic B, Bhutia YD and Ganapathy V:
Cell-surface G-protein- coupled receptors for tumor-associated
metabolites: A direct link to mitochondrial dysfunction in cancer.
Biochim Biophys Acta Rev Cancer. 1868:246–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alfarouk KO, Verduzco D, Rauch C,
Muddathir AK, Adil HH, Elhassan GO, Ibrahim ME, David Polo Orozco
J, Cardone RA, Reshkin SJ and Harguindey S: Glycolysis, tumor
metabolism, cancer growth and dissemination. A new pH-based
etiopathogenic perspective and therapeutic approach to an old
cancer question. Oncoscience. 1:777–802. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JW and Dang CV: Cancer's molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang F, Ma S, Xue Y, Hou J and Zhang Y:
LDH-A promotes malignant progression via activation of
epithelial-to-mesenchymal transition and conferring stemness in
muscle-invasive bladder cancer. Biochem Biophys Res Commun.
469:985–992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Levy DE, Kessler DS, Pine R, Reich N and
Darnell JE Jr: Interferon-induced nuclear factors that bind a
shared promoter element correlate with positive and negative
transcriptional control. Genes Dev. 2:383–393. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Williams JG: STAT signalling in cell
proliferation and in development. Curr Opin Genet Dev. 10:503–507.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
La Fortezza M, Schenk M, Cosolo A,
Kolybaba A, Grass I and Classen AK: JAK/STAT signalling mediates
cell survival in response to tissue stress. Development.
143:2907–2919. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Demaria M, Giorgi C, Lebiedzinska M,
Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE,
Watson CJ, et al: A STAT3-mediated metabolic switch is involved in
tumour transformation and STAT3 addiction. Aging (Albany NY).
2:823–842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roca Suarez AA, Van Renne N, Baumert TF
and Lupberger J: Viral manipulation of STAT3: Evade, exploit, and
injure. PLoS Pathog. 14:e10068392018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Villarino AV, Kanno Y and O'Shea JJ:
Mechanisms and consequences of Jak-STAT signaling in the immune
system. Nat Immunol. 18:374–384. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nan Y, Wu C and Zhang YJ: Interplay
between janus kinase/signal transducer and activator of
transcription signaling activated by type I interferons and viral
antagonism. Front Immunol. 8:17582017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Maycotte P, Gearheart CM, Barnard R, Aryal
S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC,
Gustafson DL and Thorburn A: STAT3-mediated autophagy dependence
identifies subtypes of breast cancer where autophagy inhibition can
be efficacious. Cancer Res. 74:2579–2590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fathi N, Rashidi G, Khodadadi A, Shahi S
and Sharifi S: STAT3 and apoptosis challenges in cancer. Int J Biol
Macromol. 117:993–1001. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li J, Liu T, Zhao L, Chen W, Hou H, Ye Z
and Li X: Ginsenoside 20(S)Rg3 inhibits the Warburg effect through
STAT3 pathways in ovarian cancer cells. Int J Oncol. 46:775–781.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Akiyama Y, Iizuka A, Kume A, Komiyama M,
Urakami K, Ashizawa T, Miyata H, Omiya M, Kusuhara M and Yamaguchi
K: Effect of STAT3 inhibition on the metabolic switch in a highly
STAT3-activated lymphoma cell line. Cancer Genomics Proteomics.
12:133–142. 2015.PubMed/NCBI
|
|
45
|
Darnell JE Jr: STAT3, HIF-1, glucose
addiction and Warburg effect. Aging (Albany NY). 2:890–891. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kwast-Welfeld J, Soong CJ, Short ML and
Jungmann RA: Identification of rat ovarian nuclear factors that
interact with the cAMP-inducible lactate dehydrogenase A subunit
promoter. J Biol Chem. 264:6941–6947. 1989.PubMed/NCBI
|
|
47
|
Short ML, Huang D, Milkowski DM, Short S,
Kunstman K, Soong CJ, Chung KC and Jungmann RA: Analysis of the rat
lactate dehydrogenase A subunit gene promoter/regulatory region.
Biochem J. 304:391–398. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Semenza GL, Jiang BH, Leung SW, Passantino
R, Concordet JP, Maire P and Giallongo A: Hypoxia response elements
in the aldolase A, enolase 1, and lactate dehydrogenase A gene
promoters contain essential binding sites for hypoxia-inducible
factor 1. J Biol Chem. 271:32529–32537. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lewis BC, Prescott JE, Campbell SE, Shim
H, Orlowski RZ and Dang CV: Tumor induction by the c-Myc target
genes rcl and lactate dehydrogenase A. Cancer Res. 60:6178–6183.
2000.PubMed/NCBI
|
|
50
|
Zhao YH, Zhou M, Liu H, Ding Y, Khong HT,
Yu D, Fodstad O and Tan M: Upregulation of lactate dehydrogenase A
by ErbB2 through heat shock factor 1 promotes breast cancer cell
glycolysis and growth. Oncogene. 28:3689–3701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cui J, Shi M, Xie D, Wei D, Jia Z, Zheng
S, Gao Y, Huang S and Xie K: FOXM1 promotes the Warburg effect and
pancreatic cancer progression via transactivation of LDHA
expression. Clin Cancer Res. 20:2595–2606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J,
Zhu Z, Gao Y and Xie K: A novel KLF4/LDHA signaling pathway
regulates aerobic glycolysis in and progression of pancreatic
cancer. Clin Cancer Res. 20:4370–4380. 2014. View Article : Google Scholar : PubMed/NCBI
|
